Sapropterin - Asubio-Pharma/BioMarin-Pharmaceutical/Daiichi-Sankyo-Company
Alternative Names: 6R-BH4; BH4; Biopten; Dapropterin; Dapropterin dihydrochloride; Kuvan; Phenoptin; Sapropterin dihydrochloride; SUN-0588; SUN0588r; T-1401; Tetrahydrobiopterin; Tetrahydrobiopterin dihydrochlorideLatest Information Update: 05 Nov 2023
At a glance
- Originator Asubio Pharma; Daiichi Sankyo Company
- Developer Asubio Pharma; BioMarin Pharmaceutical; Daiichi Sankyo Company; John Hopkins University
- Class Antianaemics; Antihypertensives; Anxiolytics; Nootropics; Pterins; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Nitric oxide synthase stimulants; Phenylalanine hydroxylase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Phenylketonuria
- No development reported Isolated systolic hypertension
- Discontinued Coronary disorders; Hypertension; Kidney disorders; Peripheral arterial disorders; Pulmonary hypertension; Sickle cell anaemia; Vascular disorders
Most Recent Events
- 28 Feb 2023 BioMarin Pharmaceutical has patents pending applications for Sapropterin in EU
- 27 Dec 2022 NDR Batch #35: No updates and not done NDR for Isolated systolic hypertension line, as no info found for this indication on company website and trial also already terminated long back.
- 31 Dec 2020 BioMarin Pharmaceutical has patent for Spropterin in USA and European union